Lilly’s Byetta bedeviling Novo Nordisk
Many analysts are recommending that investors hold off on buying stock in Novo Nordisk because rival Eli Lilly and Co. might encounter a smash hit with a version of its Byetta diabetes treatment that would be taken only once a week. Nineteen of the 34 analysts who follow the Danish insulin maker have “hold” or […]